Parnassus Investments
Parnassus Endeavor Fund
Parnassus Endeavor Fund Regeneron Pharmaceuticals Inc stake
total: 118
Parnassus Endeavor Fund REGN trades
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 1
- Reduced:
- 3
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Parnassus Endeavor Fund holds 95,378 Regeneron Pharmaceuticals Inc (REGN) shares with a market value of roughly $59.47M accounting for 1.12% of the overall portfolio. To date, the estimated cost basis is nearly $527.31 for "buy" trades and estimated average "sell" price is $722.77. Parnassus Endeavor Fund first purchased REGN in 2025 Q2, initially acquiring 101,084 shares. Since the initial investment in Regeneron Pharmaceuticals Inc (REGN), Parnassus Endeavor Fund has made 4 more transactions.
When did Parnassus Endeavor Fund buy Regeneron Pharmaceuticals Inc (REGN)?
Parnassus Endeavor Fund first invested in Regeneron Pharmaceuticals Inc (REGN) in 2025 Q2 at the reported quarter-end price of $525.00 per share.
What's the cost basis of Parnassus Endeavor Fund's REGN stake?
The estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) stake is around $527.31 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $527.31
- Weighted AVG sell price:
- $722.77
Parnassus Endeavor Fund's historical trades in Regeneron Pharmaceuticals Inc
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.12%
|
95,378
|
$623.54
|
$59,471,998
|
-2.17% (-2,117)
|
-0.03%
|
|
2026 Q1
|
1.63%
|
97,495
|
$772.64
|
$75,328,537
|
+0.98% (+950)
|
+0.02%
|
|
2025 Q4
|
1.56%
|
96,545
|
$771.87
|
$74,520,189
|
-4.43% (-4,478)
|
-0.07%
|
|
2025 Q3
|
1.21%
|
101,023
|
$562.27
|
$56,802,202
|
-0.06% (-61)
|
-0%
|
|
2025 Q2
|
1.17%
|
101,084
|
$525.00
|
$53,069,100
|
new
|
+1.17%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.